

Mindfulness in ovarian cancer

Submission date 05/12/2016	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 05/12/2016	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 16/01/2018	Condition category Cancer	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Ovarian cancer is a common form of cancer that often returns after treatment. Having cancer return can be traumatizing, causing mental distress. Mindfulness is a technique that aims patients live life in a present moment and could help patients with recurrent ovarian cancer. The aim of this study is to explore the feasibility of delivering a 6-week mindfulness based group support intervention to a cohort of ovarian cancer patients who have experienced disease recurrence.

Who can participate?

Woman aged 18 and older who have a confirmed ovarian cancer.

What does the study involve?

All participants receive a 6-week mindfulness-based intervention comprising a total of 8.5 contact hours. The programme has been specifically adapted and modified for cancer patients based around extensive qualitative research to ensure its applicability and acceptability and in this capacity it has been successfully trialled in a population of stage 4 breast cancer patients.

What are the possible benefits and risks of participating?

Not provided at time of registration.

Where is the study run from?

Queen Alexandra Hospital (UK)

When is the study starting and how long is it expected to run for?

May 2016 to May 2017

Who is funding the study?

National Institute for Health Research (UK)

Who is the main contact?

Dr Sam Watts (Scientific)

s.watts@soton.ac.uk

Contact information

Type(s)

Scientific

Contact name

Dr Sam Watts

Contact details

Aldermoor Health Centre
Aldermoor Close
Southampton
United Kingdom
SO16 5ST
+44 (0)2380 241085
s.watts@soton.ac.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

32108

Study information**Scientific Title**

A six-week programme of group mindfulness sessions to improve mental health and wellbeing in patients with recurrent ovarian cancer: a feasibility study

Acronym

MOVA

Study objectives

The aim of this study is to explore the feasibility of delivering a 6-week mindfulness based group support intervention to a cohort of ovarian cancer patients who have experienced disease recurrence.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Berkshire Research Ethics Committee, 30/08/2016, ref: 16/SC/0415

Study design

Non-randomised; Interventional; Design type: Treatment, Complementary Therapy, Psychological & Behavioural

Primary study design

Interventional

Secondary study design

Non randomised study

Study setting(s)

Hospital

Study type(s)

Quality of life

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Specialty: Cancer, Primary sub-specialty: Gynaecological Cancers; UKCRC code/ Disease: Cancer/ Malignant neoplasms of female genital organs

Interventions

All participants receive a 6-week mindfulness-based intervention comprising a total of 8.5 contact hours. The intervention has been specifically adapted and modified for cancer patients based around extensive qualitative research to ensure its applicability and acceptability and in this capacity it has been successfully trialled in a population of stage 4 breast cancer patients.

Intervention Type

Other

Primary outcome measure

Feasibility outcomes:

1. Recruitment rate
2. Response rates
3. Number of patients completing the intervention
4. Number of patients completing the 6 month follow-up
5. Qualitative assessment of the intervention
6. Quantitative data analysis

Secondary outcome measures

1. Anxiety
2. Depression
3. Quality of life
4. Diurnal cortisol variations

Overall study start date

01/05/2016

Completion date

09/05/2017

Eligibility

Key inclusion criteria

1. Any confirmed recurrence of OvCa at any stage
2. Aged 18 years and above
3. Willing to participate and provide informed consent
4. Fluent English (questionnaires validated and interviews conducted in English)

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Female

Target number of participants

Planned Sample Size: 30; UK Sample Size: 30

Key exclusion criteria

1. Additional cancer diagnoses
2. Any significant mental illness (i.e. overt psychosis, history of suicidal ideation) but not to include clinical depression and/or anxiety
3. Receiving any other psychological therapy

Date of first enrolment

09/11/2016

Date of final enrolment

01/02/2017

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

Queen Alexandra Hospital
Southwick Hill Road
Cosham

Portsmouth
United Kingdom
PO6 3LY

Sponsor information

Organisation

Portsmouth Hospitals NHS Trust

Sponsor details

De La Court House
Queen Alexandra Hospital
Southwick Hill Road
Portsmouth
England
United Kingdom
PO6 3LY

Sponsor type

Hospital/treatment centre

ROR

<https://ror.org/009fk3b63>

Funder(s)

Funder type

Government

Funder Name

National Institute for Health Research

Alternative Name(s)

National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

09/05/2018

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
HRA research summary			28/06/2023	No	No